Literature DB >> 25540317

Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers.

Rick C Helmich1, Avner Thaler2, Bart F L van Nuenen2, Tanya Gurevich2, Anat Mirelman2, Karen S Marder2, Susan Bressman2, Avi Orr-Urtreger2, Nir Giladi2, Bastiaan R Bloem2, Ivan Toni2.   

Abstract

OBJECTIVE: We investigated system-level corticostriatal changes in a human model of premotor Parkinson disease (PD), i.e., healthy carriers of the G2019S LRRK2 mutation that is associated with a markedly increased, age-dependent risk of developing PD.
METHODS: We compared 37 asymptomatic LRRK2 G2019S mutation carriers (age range 30-78 years) with 32 matched, asymptomatic nonmutation carriers (age range 30-74 years). Using fMRI, we tested the hypothesis that corticostriatal connectivity in premotor PD shifts from severely affected to less affected striatal subregions, as shown previously in symptomatic PD. Specifically, we predicted that in premotor PD, the shift in corticostriatal connectivity would follow the same gradient of striatal dopamine depletion known from overt PD, with the dorsoposterior putamen being more affected than the ventroanterior putamen.
RESULTS: The known parallel topology of corticostriatal loops was preserved in each group, but the topography of putamen connectivity shifted. In LRRK2 G2019S mutation carriers, the right inferior parietal cortex had reduced functional connectivity with the dorsoposterior putamen but increased connectivity with the ventroanterior putamen, as compared with noncarriers. This shift in functional connectivity increased with age in LRRK2 G2019S mutation carriers.
CONCLUSIONS: Asymptomatic LRRK2 G2019S mutation carriers show a reorganization of corticostriatal circuits that mirrors findings in idiopathic PD. These changes may reflect premotor basal ganglia dysfunction or circuit-level compensatory changes.
© 2014 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25540317      PMCID: PMC4336002          DOI: 10.1212/WNL.0000000000001189

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  38 in total

1.  Motion or activity: their role in intra- and inter-subject variation in fMRI.

Authors:  Torben E Lund; Minna D Nørgaard; Egill Rostrup; James B Rowe; Olaf B Paulson
Journal:  Neuroimage       Date:  2005-03-29       Impact factor: 6.556

2.  Basal ganglia functional connectivity based on a meta-analysis of 126 positron emission tomography and functional magnetic resonance imaging publications.

Authors:  Ronald B Postuma; Alain Dagher
Journal:  Cereb Cortex       Date:  2005-12-22       Impact factor: 5.357

Review 3.  Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging.

Authors:  Michael D Fox; Marcus E Raichle
Journal:  Nat Rev Neurosci       Date:  2007-09       Impact factor: 34.870

4.  A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery.

Authors:  Stéphanie Mounayar; Sabrina Boulet; Dominique Tandé; Caroline Jan; Mathias Pessiglione; Etienne C Hirsch; Jean Féger; Marc Savasta; Chantal François; Léon Tremblay
Journal:  Brain       Date:  2007-09-13       Impact factor: 13.501

5.  Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations.

Authors:  Jennifer Kachergus; Ignacio F Mata; Mary Hulihan; Julie P Taylor; Sarah Lincoln; Jan Aasly; J Mark Gibson; Owen A Ross; Timothy Lynch; Joseph Wiley; Haydeh Payami; John Nutt; Demetrius M Maraganore; Krzysztof Czyzewski; Maria Styczynska; Zbigniew K Wszolek; Matthew J Farrer; Mathias Toft
Journal:  Am J Hum Genet       Date:  2005-02-22       Impact factor: 11.025

6.  PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.

Authors:  John R Adams; Hinke van Netten; Michael Schulzer; Edwin Mak; Jessamyn Mckenzie; Audrey Strongosky; Vesna Sossi; Thomas J Ruth; Chong S Lee; Matthew Farrer; Thomas Gasser; Ryan J Uitti; Donald B Calne; Zbigniew K Wszolek; A Jon Stoessl
Journal:  Brain       Date:  2005-08-04       Impact factor: 13.501

Review 7.  A network dysfunction perspective on neurodegenerative diseases.

Authors:  Jorge J Palop; Jeannie Chin; Lennart Mucke
Journal:  Nature       Date:  2006-10-19       Impact factor: 49.962

8.  An effect of dopamine depletion on decision-making: the temporal coupling of deliberation and execution.

Authors:  Mathias Pessiglione; Virginie Czernecki; Bernard Pillon; Bruno Dubois; Michael Schüpbach; Yves Agid; Léon Tremblay
Journal:  J Cogn Neurosci       Date:  2005-12       Impact factor: 3.225

9.  Sensorimotor integration is abnormal in asymptomatic Parkin mutation carriers: a TMS study.

Authors:  T Bäumer; P P Pramstaller; H R Siebner; S Schippling; J Hagenah; M Peller; C Gerloff; C Klein; A Münchau
Journal:  Neurology       Date:  2007-11-20       Impact factor: 9.910

10.  Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study.

Authors:  Anna Brück; Sargo Aalto; Elina Nurmi; Tero Vahlberg; Jörgen Bergman; Juha O Rinne
Journal:  Mov Disord       Date:  2006-07       Impact factor: 10.338

View more
  24 in total

Review 1.  Functional and behavioral consequences of Parkinson's disease-associated LRRK2-G2019S mutation.

Authors:  Deanna L Benson; Bridget A Matikainen-Ankney; Ayan Hussein; George W Huntley
Journal:  Biochem Soc Trans       Date:  2018-12-04       Impact factor: 5.407

2.  Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers.

Authors:  Kyle B Fraser; Mark S Moehle; Roy N Alcalay; Andrew B West
Journal:  Neurology       Date:  2016-02-10       Impact factor: 9.910

Review 3.  LRRK2 in Parkinson disease: challenges of clinical trials.

Authors:  Eduardo Tolosa; Miquel Vila; Christine Klein; Olivier Rascol
Journal:  Nat Rev Neurol       Date:  2020-01-24       Impact factor: 42.937

4.  LRRK2 and GBA Variants Exert Distinct Influences on Parkinson's Disease-Specific Metabolic Networks.

Authors:  Katharina A Schindlbeck; An Vo; Nha Nguyen; Chris C Tang; Martin Niethammer; Vijay Dhawan; Vicky Brandt; Rachel Saunders-Pullman; Susan B Bressman; David Eidelberg
Journal:  Cereb Cortex       Date:  2020-05-14       Impact factor: 5.357

5.  Network abnormalities among non-manifesting Parkinson disease related LRRK2 mutation carriers.

Authors:  Yael Jacob; Keren Rosenberg-Katz; Tanya Gurevich; Rick C Helmich; Bastiaan R Bloem; Avi Orr-Urtreger; Nir Giladi; Anat Mirelman; Talma Hendler; Avner Thaler
Journal:  Hum Brain Mapp       Date:  2019-02-21       Impact factor: 5.038

Review 6.  Resting-state functional reorganization in Parkinson's disease: An activation likelihood estimation meta-analysis.

Authors:  Masoud Tahmasian; Simon B Eickhoff; Kathrin Giehl; Frank Schwartz; Damian M Herz; Alexander Drzezga; Thilo van Eimeren; Angela R Laird; Peter T Fox; Habibolah Khazaie; Mojtaba Zarei; Carsten Eggers; Claudia R Eickhoff
Journal:  Cortex       Date:  2017-04-08       Impact factor: 4.027

Review 7.  Loss of gait control assessed by cognitive-motor dual-tasks: pros and cons in detecting people at risk of developing Alzheimer's and Parkinson's diseases.

Authors:  Maroua Belghali; Nathalie Chastan; Fabien Cignetti; Damien Davenne; Leslie M Decker
Journal:  Geroscience       Date:  2017-05-27       Impact factor: 7.713

8.  Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.

Authors:  Bridget A Matikainen-Ankney; Nebojsa Kezunovic; Roxana E Mesias; Yuan Tian; Frances M Williams; George W Huntley; Deanna L Benson
Journal:  J Neurosci       Date:  2016-07-06       Impact factor: 6.167

Review 9.  Imaging Markers of Progression in Parkinson's Disease.

Authors:  Antonio P Strafella; Nico I Bohnen; Nicola Pavese; David E Vaillancourt; Thilo van Eimeren; Marios Politis; Alessandro Tessitore; Christine Ghadery; Simon Lewis
Journal:  Mov Disord Clin Pract       Date:  2018-10-09

Review 10.  Merging Clinical and Imaging Biomarkers to Tackle Parkinson's Disease.

Authors:  Marina Picillo; Paolo Barone; Maria Teresa Pellecchia
Journal:  Mov Disord Clin Pract       Date:  2017-08-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.